MedCity News January 17, 2025
Frank Vinluan

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an initial treatment for this type of blood cancer.

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma, making it the first in its class approved as a first-line therapy for this rare and aggressive type of blood cancer.

The FDA expanded approval of the drug, acalabrutinib, to include previously untreated MCL in adults who are also ineligible for a hematopoietic stem cell transplant that is a treatment option for younger patients. As a first-line therapy, the AstraZeneca drug must be used in combination with bendamustine and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Opinion: STAT+: How the FDA and CMS worked together on a new approach to paying for digital mental health treatments
FDA's health kick: New food labels, banned food dyes, and more
FDA Releases Draft Guidance on Evaluating the Risk and Credibility of AI Used in Establishing Drug and Device Safety, Effectiveness, and Quality
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
Watchdog flags flaws in FDA's fast-track drug approvals

Share This Article